866-997-4948 (US-Canada Toll Free)

Cancer Symptoms Partnering 2007-2013

Published By :

Current Partnering

Published Date : 2013-10-08

Category :

Biotechnology

No. of Pages : 150

Product Synopsis

The Cancer Symptoms Partnering 2007-2013 report provides understanding and access to the cancer symptoms partnering deals and agreements entered into by the worlds leading healthcare companies.   Trends in solid tumor cancer partnering deals Top solid tumor cancer deals by value Deals listed by company A-Z, industry sector, stage of development, technology type   The Solid Tumor Cancer Partnering 2007-2013 provides understanding and access to the solid tumor cancer partnering deals and agreements entered into by the worlds leading healthcare companies.   This report provides details of thelatest cancer symptoms agreements announced in the healthcare sectors, covering:   Symptoms Oral mucositis Cancer pain... Read More

Table Of Content

TABLE OF CONTENT

Executive Summary
 
Chapter 1 – Introduction
 
Chapter 2 – Trends in cancer symptoms partnering
2.1. Introduction
2.2. Cancer symptoms partnering over the years
2.3. Bigpharma cancer symptoms dealmaking activity
2.4. Cancer symptoms partnering by deal type
2.5. Cancer symptoms partnering industry sector
2.6. Cancer symptoms partnering by stage of development
2.7. Cancer symptoms partnering by technology type
2.8. Disclosed financial deal terms for cancer symptoms partnering
2.8.1 Cancer symptoms headline values
2.8.2 Cancer symptoms upfront payments
2.8.3 Cancer symptoms milestone payments
2.8.4 Cancer symptoms royalty rates
 
Chapter 3 – Leading cancer symptoms deals
3.1. Introduction
3.2. Top cancer symptoms deals by value
3.3. Top cancer symptoms deals involving bigpharma
 
Chapter 4 – Dealmaking directory
4.1. Introduction
4.2. Company A-Z
4.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
4.4. By industry sector
Academic
Bigpharma
Biotech
Drug delivery
Medical device
Diagnostic
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
4.5. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
4.6. By technology type
Analysis
Animal models
Assays
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Cell culture
Cell therapy
Clinical testing
Diagnostic - companion
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Imaging
Industrial chemicals
In vitro models
Monoclonal antibodies
Nanotechnology
Oligonucleotide
Peptides
Personalised medicine
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Stem cells
Vaccines
 
Chapter 5 – Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
 
Appendices
 
Appendix 1 – Deal type definitions
 
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports

List of Tables

NA

List of Figures

 
Figure 1: Cancer symptoms partnering since 2007
Figure 2: Bigpharma – top 50 – Cancer symptoms deals 2007 to 2013
Figure 3: Bigpharma cancer symptoms deal frequency – 2007 to 2013
Figure 4: Cancer symptoms partnering by deal type since 2007
Figure 5: Cancer symptoms partnering by industry sector since 2007
Figure 6: Cancer symptoms partnering by stage of development since 2007
Figure 7: Cancer symptoms partnering by technology type since 2007
Figure 8: Cancer symptoms deals with a headline value
Figure 9: Cancer symptoms deals with upfront payment values
Figure 10: Cancer symptoms deals with milestone payments
Figure 11: Cancer symptoms deals with royalty rates, %
Figure 12: Top cancer symptoms deals by value since 2007
Figure 13: Top cancer symptoms deals signed by bigpharma value since 2007
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports

  • Rhinoconjunctivitis Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2014 - 2020

    By - Transparency

    Rhinoconjunctivitis is a combination of rhinitis and conjunctivitis and is one of the most common allergic reactions across the globe. It is an inflammatory disorder which affects nasal and conjunctival mucosa and is induced as a result of hypersensitive immune response. Rhinoconjunctivitis causes symptoms of allergic rhinitis such as sneezing, watery mucus, itchy nose, and nasal congestion, as well as conjunctivitis which include burning sensation, tears and redness of eyes. These symptoms may also be accompanied by systemic symptoms such as poor sleep, irritability and fatigue. Allergic...

  • Light Duty Hybrid Vehicles Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

    By - Transparency

    A vehicle that utilizes two or more different fuel sources to operate and to move the vehicle is known as a hybrid vehicle. Such term is often referred to the electric hybrid vehicles, which merge one or more electric motors to an internal combustion (IC) engine. There are also other several mechanisms to utilize the captured energy such as human–hybrid (human-electric) vehicles. These vehicles are environmentally friendly and are being promoted by automobile & automotive manufacturers and local governments. Hybrid vehicles are often powered by a number of sources such as...

  • Anti-Migraine Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

    By - Transparency

    Antimigraine drugs are the therapeutic agents indicated to use against migraine headaches. Migraine is characterized by recurrent attacks of moderate to severe headaches along with other nervous system symptoms. Migraine is more common in women than men, majorly due to the fluctuations in the harmone levels. According to a Medline article, around 12% of the U.S. population suffers from migraine headaches. The two major types of migraine are classic and common. Classic migraine is characterized by sudden change in eye sight and experience partial blindness or double vision. On the...